202 related articles for article (PubMed ID: 34992691)
1. Effects of trans-(±)-kusunokinin on chemosensitive and chemoresistant ovarian cancer cells.
Mad-Adam N; Rattanaburee T; Tanawattanasuntorn T; Graidist P
Oncol Lett; 2022 Feb; 23(2):59. PubMed ID: 34992691
[TBL] [Abstract][Full Text] [Related]
2. Anticancer Activity of (±)-Kusunokinin Derivatives towards Cholangiocarcinoma Cells.
Rattanaburee T; Sermmai P; Tangthana-Umrung K; Thongpanchang T; Graidist P
Molecules; 2022 Nov; 27(23):. PubMed ID: 36500383
[TBL] [Abstract][Full Text] [Related]
3. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
4. Trans-(-)-Kusunokinin: A Potential Anticancer Lignan Compound against HER2 in Breast Cancer Cell Lines?
Rattanaburee T; Tanawattanasuntorn T; Thongpanchang T; Tipmanee V; Graidist P
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361688
[TBL] [Abstract][Full Text] [Related]
5. Anticancer activity of synthetic (±)-kusunokinin and its derivative (±)-bursehernin on human cancer cell lines.
Rattanaburee T; Thongpanchang T; Wongma K; Tedasen A; Sukpondma Y; Graidist P
Biomed Pharmacother; 2019 Sep; 117():109115. PubMed ID: 31220743
[TBL] [Abstract][Full Text] [Related]
6. (-)-Kusunokinin and piperloguminine from Piper nigrum: An alternative option to treat breast cancer.
Sriwiriyajan S; Sukpondma Y; Srisawat T; Madla S; Graidist P
Biomed Pharmacother; 2017 Aug; 92():732-743. PubMed ID: 28586745
[TBL] [Abstract][Full Text] [Related]
7. Oridonin effectively reverses cisplatin drug resistance in human ovarian cancer cells via induction of cell apoptosis and inhibition of matrix metalloproteinase expression.
Ma S; Tan W; Du B; Liu W; Li W; Che D; Zhang G
Mol Med Rep; 2016 Apr; 13(4):3342-8. PubMed ID: 26935490
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of CSF1R and AKT by (±)-kusunokinin hinders breast cancer cell proliferation.
Rattanaburee T; Tipmanee V; Tedasen A; Thongpanchang T; Graidist P
Biomed Pharmacother; 2020 Sep; 129():110361. PubMed ID: 32535390
[TBL] [Abstract][Full Text] [Related]
9. (-)-Kusunokinin inhibits breast cancer in N-nitrosomethylurea-induced mammary tumor rats.
Tedasen A; Dokduang S; Sukpondma Y; Lailerd N; Madla S; Sriwiriyajan S; Rattanaburee T; Tipmanee V; Graidist P
Eur J Pharmacol; 2020 Sep; 882():173311. PubMed ID: 32619673
[TBL] [Abstract][Full Text] [Related]
10. β-elemene effectively suppresses the growth and survival of both platinum-sensitive and -resistant ovarian tumor cells.
Lee RX; Li QQ; Reed E
Anticancer Res; 2012 Aug; 32(8):3103-13. PubMed ID: 22843880
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of coiled coil domain containing protein 69 enhances platinum-induced apoptosis in ovarian cancer cells.
Cui L; Liang B; Yang Y; Zhu M; Kwong J; Zheng H; Wang CC
Oncotarget; 2017 Nov; 8(60):101634-101648. PubMed ID: 29254192
[TBL] [Abstract][Full Text] [Related]
12. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
13. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
15. Potential Stereoselective Binding of
Chompunud Na Ayudhya C; Graidist P; Tipmanee V
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807438
[TBL] [Abstract][Full Text] [Related]
16. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
Tang X; Lu M; Li C; Deng S; Li M
Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
[TBL] [Abstract][Full Text] [Related]
17. The p53 upregulated modulator of apoptosis (PUMA) chemosensitizes intrinsically resistant ovarian cancer cells to cisplatin by lowering the threshold set by Bcl-x(L) and Mcl-1.
Yuan Z; Cao K; Lin C; Li L; Liu HY; Zhao XY; Liu L; Deng HX; Li J; Nie CL; Wei YQ
Mol Med; 2011; 17(11-12):1262-74. PubMed ID: 21863213
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells.
Guo J; Satoh K; Tabata S; Mori M; Tomita M; Soga T
BMC Cancer; 2021 Feb; 21(1):174. PubMed ID: 33596851
[TBL] [Abstract][Full Text] [Related]
19. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
Asselin E; Mills GB; Tsang BK
Cancer Res; 2001 Mar; 61(5):1862-8. PubMed ID: 11280739
[TBL] [Abstract][Full Text] [Related]
20. Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines.
Tsuruta Y; Mandai M; Konishi I; Kuroda H; Kusakari T; Yura Y; Hamid AA; Tamura I; Kariya M; Fujii S
Eur J Cancer; 2001 Mar; 37(4):531-41. PubMed ID: 11267864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
